Incyte Corp.

NASDAQ:INCY   3:59:52 PM EDT
78.48
+1.13 (+1.46%)
Products, Regulatory

Incyte Announces Positive Phase 3 Reach3 Study Data Published In Nejm For Ruxolitinib (Jakafi®) In Chronic Graft-Versus-Host Disease

Published: 07/14/2021 21:11 GMT
Incyte Corp. (INCY) - Incyte Announces Positive Phase 3 Reach3 Study Data Published in Nejm for Ruxolitinib (jakafi®) in Chronic Graft-versus-host Disease.
Incyte Corp - Phase 3 Reach3 Data Show That Ruxolitinib (jakafi®) Significantly Improved Overall Response Rate (orr) at Week 24 (49.7% Versus.
25.6%).
Incyte Corp - Ruxolitinib Also Demonstrated Statistically Significant and Clinically Meaningful Improvements in Key Secondary Endpoints.
Incyte - New Subgroup Analysis Found That Patients on Ruxolitinib Had Better Outcomes Regardless of Individual Organs Affected at Baseline.